UPLOAD Filing
Aprea Therapeutics, Inc.
Date: April 27, 2026 · CIK: 0001781983 · Accession: 0000000000-26-004268
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295247
Letter
April 27, 2026 Oren Gilad Chief Executive Officer Aprea Therapeutics, Inc. 3805 Old Easton Road Doylestown, PA 18902 Re: Aprea Therapeutics, Inc. Registration Statement on Form S-3 Filed April 22, 2026 File No. 333-295247 Dear Oren Gilad: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Patrick O'Malley, Esq.
Show Raw Text
April 27, 2026
Oren Gilad
Chief Executive Officer
Aprea Therapeutics, Inc.
3805 Old Easton Road
Doylestown, PA 18902
Re: Aprea Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 22, 2026
File No. 333-295247
Dear Oren Gilad:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Patrick O'Malley, Esq.